Results 181 to 190 of about 80,955 (206)

The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors

Cell Chemical Biology, 2022
Vinayak Palve, Daniel S Bejan, Alvaro N A Monteiro   +2 more
exaly  

An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer

Cancer Chemotherapy and Pharmacology, 2022
Jing Wang, Chong Lu, Yu Kang
exaly  

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

Cancers, 2020
Elizabeth K Lee, Ursula A Matulonis, Matulonis Ursula A   +2 more
exaly  

Guiding ATR and PARP inhibitor combinations with chemogenomic screens

Cell Reports, 2022
Jordan T F Young, Michael Zinda
exaly  

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Annals of Oncology, 2023
E Pujade-Lauraine, F Marme, K Lindemann   +2 more
exaly  

PARP inhibitors: pitfalls and promises

The Lancet Oncology, 2013
Jeffrey R, Infante, Howard A, Burris
openaire   +2 more sources

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Cancer Cell, 2018
Ewa Gogola, Wouter W Wiegant, Roebi de Bruijn   +2 more
exaly  

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects

EBioMedicine, 2018
Chenying Li, Jie Jin, Jiansong Huang
exaly  

<p>Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer</p>

Cancer Management and Research, 2019
Xuan Jiang, Weihua Li, Huimin Bai
exaly  

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Cell Reports, 2016
Shawn F Johnson, Daniel G Stover, Shiliang A Cao   +2 more
exaly